Discover VIP (Vasoactive Intestinal Peptide) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide with potent anti-inflammatory, vasodilatory, and immunomodulatory properties, commonly studied in the context of chronic inflammatory response syndrome (CIRS) and lung health. This data reveals the dose amounts, vial sizes, and diluent volumes researchers most commonly select when setting up their VIP reconstitution protocol.
VIP — Vasoactive Intestinal Peptide — is a 28-amino acid neuropeptide first isolated from porcine duodenal extracts by Said and Mutt in 1970, and it acts through the VPAC1 and VPAC2 G-protein-coupled receptors as a broad immunomodulator, vasodilator, and bronchodilator. The published clinical record for VIP as a therapeutic spans several distinct programs: aviptadil — the synthetic VIP formulation developed by Mondo Biotech and later by NeuroRx and Relief Therapeutics — was advanced into pulmonary arterial hypertension and acute respiratory distress syndrome trials, and was the subject of a high-profile but ultimately negative COVID-19 ARDS Phase 2/3 program read out in 2021-2022. Inhaled aviptadil has also been studied in sarcoidosis and idiopathic pulmonary fibrosis at small clinical scales.
VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide most often sourced for respiratory, anti-inflammatory, and autonomic research. Its synthetic form, aviptadil, has been studied for pulmonary hypertension and COVID-19 respiratory failure. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
VIP binds two G-protein-coupled receptors (VPAC1 and VPAC2) widely expressed in vascular smooth muscle, alveolar type II pneumocytes, immune cells, and the CNS. VPAC2 activation in alveolar type II cells is thought to up-regulate surfactant production and reduce pro-inflammatory cytokine release, the rationale that motivated the aviptadil COVID-19 ARDS program.
Inhaled aviptadil was evaluated in sarcoidosis (Prasse et al., Eur Respir J 2010) with positive bronchoalveolar-lavage cytokine effects but no consistent functional improvement. The NIH-sponsored ACTIV-3b ARDS COVID-19 trial (TESICO) of intravenous aviptadil did not meet its primary endpoint (Wright et al., Lancet Respir Med 2023). Earlier work in erectile dysfunction (Invicorp, fixed combination with phentolamine) is approved in some European markets.
VIP has a reported half-life of ~1–2 min, and the dose intervals researchers model most often fall around multiple times daily (often nebulized/intranasal). Vasoactive intestinal peptide is degraded within a couple of minutes in the bloodstream, so there is no buildup at all — it is dosed frequently and acts only during brief exposure. It is catalogued under Memory Peptides on WPA.
82 VIP reconstitution calculations have been logged by the WPA community. The most common dose entered is 100mcg (26 calculations). The median dose across all sessions is 150mcg. The most common bacteriostatic water volume is 3mL. The most popular vial size is 5mg (52 sessions). The most common dosing frequency is 5x/week (8 logged protocols), followed by once weekly (3).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.